GlassScriptPhysician profile
Jeffrey Hakim
NPI 1164955373
$8,899.93
in general payments reported to CMS, 2019-2025
7 companies · $235 in 2025
The $235 reported for 2025 was less than what a typical Neurological Surgery provider received nationally (typical 2025 total: $604).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $102 · 2023: $131 · 2024: $8,432 · 2025: $235.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $7,091 · Food and Beverage: $1,707.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $7,091.14 |
| Food and Beverage | $1,706.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Penumbra, INC. | $6,337.73 | 2021-2025 | Penumbra System, Benchmark, Penumbra Coil 400 |
| Globus Medical, INC. | $1,931.05 | 2024 | Excelsiusgps Robotic Navigation System, Nvm5, Excelsius Deformity |
| Imperative Care, INC | $263.78 | 2024 | Zoom 88-T Large Distal Platform |
| Stryker Corporation | $133.23 | 2023-2024 | Neuroform Atlas, Target |
| Microvention, INC. | $109.63 | 2023-2024 | Scepter C, Balloon Catheter, Hydrosoft Advanced |
| Medtronic, INC. | $107.00 | 2025 | Pipeline |
| Chiesi USA, INC. | $17.51 | 2024 | Cleviprex, Kengreal |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Hakim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.